
Carisma Therapeutics Welcomes New Board Member John Hohneker Amid Company Evolution
PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM), a trailblazer in engineered macrophage development for immunotherapies, announced a significant transition in its leadership team. Effective April 1, 2024, John Hohneker, …
Carisma Therapeutics Welcomes New Board Member John Hohneker Amid Company Evolution Read More